Efficacy and Safety of Cyclosporine and Tacrolimus in Rheumatoid Arthritis: A Systematic Review and Meta-Analysis
- 문서 유형
- 연구출판물 · 리뷰논문
- 등재
- SCIEScopus
- 저널 순위
- JCR Q1Scopus Q1
- 저널
- INTERNATIONAL JOURNAL OF CLINICAL PRACTICE2026(1) · 2026
- 피인용
- Web of Science 2Scopus 1
- FWCI (Scopus)
- 0
- JCR IF
- JCR 2024 2.4
- ISSN
- 1368-5031
저자
- Kim, Geuntae제1저자Kosin Univ, Coll Med, Kosin Univ Gospel Hosp, Div Rheumatol,Dept Internal Med, Busan, South Korea
- Shim, Sung RyulKonyang Univ, Coll Med, Dept Biomed Informat, Daejeon, South Korea
- Seo, YoungseobKorea Res Inst Stand & Sci, Emerging Res Instruments Grp, Daejeon, South Korea
- 선호근교신저자Pusan Natl Univ, Dept Stat, Busan, South Korea
초록
Aims: This study aimed to evaluate the efficacy and safety of calcineurin inhibitors (CNIs), cyclosporine (CSA), and tacrolimus (TAC) in patients with active rheumatoid arthritis (RA) based on randomized controlled trials (RCTs). Methods: A systematic literature search of PubMed, the Cochrane Library, and EMBASE was conducted to identify RCTs comparing CSA and TAC with placebo in RA. Outcomes included American College of Rheumatology (ACR) responses, assessments of tender and swollen joint counts, inflammatory markers, global assessments, and safety endpoints. The primary efficacy outcome was the ACR20 response rate, and the primary safety outcome was the mean increment in serum creatinine (s-Cr). Subgroup analyses were performed to assess dose-dependent effects. Results: Eleven RCTs (7 CSA, 4 TAC) including 1793 patients were analyzed. Both CSA (RR 1.559, 95% CI 1.099; 2.213, p = 0.013) and TAC (RR 2.139, 95% CI 1.769; 2.586, p < 0.001) significantly improved ACR20 response rates compared to placebo. Secondary efficacy outcomes showing significant differences from placebo were more frequently observed in TAC than in CSA. TAC showed less dose-dependence, whereas CSA showed a more dose-dependent trend. Regarding safety, CSA was associated with dose-dependent increases in s-Cr and secondary safety outcomes. TAC showed a mild but consistent increase in s-Cr regardless of dose, and no significant increase in secondary safety outcomes was observed at lower doses. At lower doses, both drugs maintained efficacy and were associated with fewer adverse events (AEs). Conclusions: CSA and TAC were effective in patients with RA who had an inadequate response to disease-modifying antirheumatic drugs. Both drugs maintained efficacy and were associated with fewer AEs at lower doses. These findings provide context for considering lower-dose CNI regimens in selected patient populations. However, concerns about long-term safety remain, and further long-term studies are needed to clarify the role of CNIs in the treatment of RA.
식별자
- Scopus EID
- 2-s2.0-105031453552
- WoS UID
- 001703275700001



로그인
연구물 목록으로